Abstract：
Nowadays, there is a wide range of deficiencies in treatment of diseases. These limitations are correlated with the inefficient ability of current modalities in the prognosis, diagnosis, and treatment of diseases. Therefore, there is a fundamental need for the development of novel approaches to overcome the mentioned restrictions. Chitosan (CS) nanoparticles, with remarkable physicochemical and mechanical properties, are FDA-approved biomaterials with potential biomedical aspects, like serum stability, biocompatibility, biodegradability, mucoadhesivity, non-immunogenicity, anti-inflammatory, desirable pharmacokinetics and pharmacodynamics, etc. CS-based materials are mentioned as ideal bioactive materials for fabricating nanofibrous scaffolds. Sustained and controlled drug release and in situ gelation are other potential advantages of these scaffolds. This review highlights the latest advances in the fabrication of innovative CS-based nanofibrous scaffolds as potential bioactive materials in regenerative medicine and drug delivery systems, with an outlook on their future applications.
摘要：
如今,疾病的治疗存在广泛的缺陷。这些限制与当前模式在预后中的低效能力有关，诊断,和治疗疾病。因此,有一个基本的需要开发新的方法来克服上述限制。壳聚糖(CS)纳米颗粒,具有显著的物理化学和机械性能，是FDA批准的具有潜在生物医学方面的生物材料，比如血清稳定性，生物相容性，生物降解性，粘膜粘附性,非免疫原性，抗炎,理想的药代动力学和药效学，等。基于CS的材料被提及为用于制造纳米纤维支架的理想生物活性材料。持续和受控的药物释放和原位凝胶化是这些支架的其他潜在优点。这篇综述强调了基于CS的创新纳米纤维支架作为再生医学和药物递送系统中潜在的生物活性材料的制造的最新进展，展望其未来应用。
